#Metabolic Disease

Lead report

Syntax Bio Closes $14.4M Series A, Adds New CBO and Board Members

Gene editing company Syntax Bio expands its Series A to $14.4 million, appoints a new Chief Business Officer and two independent directors. Funds will advance metabolic disease gene therapy pipeline and technology platform.